ClinicalTrials.gg

Program

vemzatatug vedotin

Its studies are mostly in Multiple Myeloma, led by AstraZeneca.

Furthest: phase 2, since Oct 11, 20231 company-led study, 1 open or runningNext primary completion: Jan 24, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Oct 11, 2023Oct 11, 2023Jan 24, 2028phase 2 · NCT06106945
  • Named in AstraZeneca’s own pipeline as AZD0305, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06106945 · 226 planned · United States, Australia, Brazil and more
  2. Oct 30, 2026Primary completion moved from 2027-08-16 to 2028-01-24Date moved laterphase 2 · +5 months · NCT06106945

Ahead

  1. Jan 24, 2028Primary completion: phase 2 study in Multiple MyelomaNCT06106945

TargetBeta

“An antibody-drug conjugate (ADC) composed of vemzatatug, a monoclonal antibody directed against the human G-protein coupled receptor family C group 5 member D (GPRC5D) conjugated to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential…”NCIt, read by Claude

Other programs on GPRC5D

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
arlocabtagene autoleucelBristol-Myers Squibbphase 33
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
Anti-GPRC5D Monoclonal Antibody SAR446523Sanofiphase 11
tunlucabtagene autoleucelBristol-Myers Squibbphase 11
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06106945Multiple Myeloma · United States, Australia, Brazil and more2RecruitingJan 24, 2028226

How it is read

Names in the registry

  • “AZD0305”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.